• Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit

Adapting to Transformative Changes in the Management of Multiple Myeloma

Format

Expert Perspective

Time to Complete

30 minutes

Released

June 17, 2014

Expires

June 17, 2015

Maximum Credits

0.50 / AMA PRA Category 1 Credit(s)TM

Accredited Provider

Jointly sponsored by Penn State College of Medicine, Curatio CME Institute, and the Multiple Myeloma Research Foundation

Commercial Supporter

Support for this activity has been provided through educational grants from Celgene, Millennium: The Takeda Oncology Company, and Onyx Pharmaceuticals

Program Description

Physicians may be hesitant to apply a patient-tailored approach to multiple myeloma treatment, especially with respect to the selection of optimal therapy combinations and sequences that integrate new agents aimed at maximizing treatment response and survival. This symposium will address practical applications of an individualized approach to management of patients with multiple myeloma. Case-based and panel discussions will focus on strategies to combine patient-, disease-, and cytogenetic-specific factors to assess risk, define prognosis, and select therapies for newly diagnosed and relapsed/refractory disease that result in maximal response rate and duration.

Intended Audience

This scientific program is designed to meet the current educational needs of hematologists-oncologists and medical oncologists involved in the care of patients with multiple myeloma.

Educational Objectives

After taking part in this educational activity, participants have an improved ability to:

  • Outline an individualized treatment plan to achieve the desired response while balancing the risk of toxicities in high-risk and standard-risk patients with myeloma
  • Incorporate the latest clinical trial advances in multiple myeloma management to achieve and prolong a maximal response

Disclosures

Penn State College of Medicine and Curatio CME Institute adhere to ACCME Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and the program sponsors have a process in place to resolve any conflict of interest. Complete disclosure is provided below under the Faculty subheading below. Speakers are also required to openly disclose discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

Faculty

Faith Davies, MBBCh, MRCP, MD, FRCPath
Senior Cancer Fellow, Cancer Research UK
Consultant Hematologist, Institute of Cancer Research, Royal Marsden Hospital
London, UK

Faith Davies, MBBCh, MRCP, MD, FRCPath, reports the following disclosures: Speaker: Celgene, Novartis, Merck Sharp & Dohme, and Janssen; Advisory Board: Celgene, Novartis, Merck Sharp & Dohme, Janssen, and Onyx

Rafael Fonseca, MD
Getz Family Professor of Cancer
Mayo Clinic
Scottsdale, AZ

Rafael Fonseca, MD, reports the following disclosures: Consultant: Medtronic, Otsuka, Celgene, Genzyme, Bristol-Myers Squibb, Lilly, Onyx, Binding Site, Millennium, and Amgen; Research Grants: Cylene, and Onyx; Patent: Prognostication of multiple myeloma based on genetic categorization of disease

Gregory J. Orloff, MD
Virginia Cancer Specialists
Fairfax, VA

Gregory J. Orloff, MD, reports no relevant financial relationships to disclose.

Donna E. Reece, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Donna E. Reece, MD, reports the following disclosures: Speaker: Celgene, Janssen, and Novartis; Consultant: Janssen, Celgene, and Onyx; Advisory Board: Celgene; Research Funding: Bristol-Myers Squibb, Millennium, and Otsuka; Dr. Reece will discuss the unlabeled or investigational use of a commercial product

Paul G. Richardson, MD
RJ Corman Professor of Medicine, Harvard Medical School
Clinical Director, Jerome Lipper Center for Multiple Myeloma, Dana-Farber Cancer Institute
Boston, MA

Paul G. Richardson, MD: Advisory Board: Bristol-Myers Squibb, Celgene, Johnson & Johnson, Millennium, and Novartis

Robert M. Rifkin, MD, FACP
Clinical Associate Professor of Medicine
Department of Internal Medicine
Division of Medical Oncology
University of Colorado
Denver, CO

Robert M. Rifkin, MD, FACP, reports the following disclosures: Speaker: Millennium and Onyx; Advisory Board: Celgene, Millennium, and Onyx

Pieter Sonneveld, MD
Professor of Hematology and Chairman
Erasmus Medical Center Cancer Institute
Rotterdam, The Netherlands

Pieter Sonneveld, MD, reports the following disclosures: Speaker: Celgene, Janssen, Onyx, and Novartis; Consultant: Celgene, Janssen, Onyx, and Novartis; Research Support: Celgene, Janssen, and Onyx

_____________

Click here for full faculty biographies.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine, Curatio CME Institute, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Penn State College of Medicine designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclaimer

The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, Penn State College of Medicine, the Multiple Myeloma Research Foundation, Celgene Corporation, Millennium: The Takeda Oncology Company, or Onyx Pharmaceuticals do not recommend the use of any agent outside the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, Penn State College of Medicine, the Multiple Myeloma Research Foundation, Celgene Corporation, Millennium: The Takeda Oncology Company, and Onyx Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions

To obtain credit, a score of 80% or better is required. This CE is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can then access at any time.

For questions regarding the content of this activity, please contact daniel.duch@curatiocme.com.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course #G5356-14-T.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

Penn State Privacy Policy
Penn State is committed to online privacy and confidentiality. This website is managed by myCME, and their printed privacy policy (below) applies to this site. CME credit for this activity is provided by Penn State College of Medicine. If you register for CME credit for this educational activity, myCME will forward relevant personally identifiable information to Penn State College of Medicine so that we can maintain records concerning credits we issue to you. We may share aggregated data concerning registrations, post-tests, and evaluations on request of our joint sponsors and/or commercial supporters. We will not share any personally identifiable information. Penn State College of Medicine may use the information you provide on this site to contact you about your CME credit or other relevant educational activities provided through Penn State College of Medicine. For more information, contact ContinuingEd@hmc.psu.edu.

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Add to Queue